- 作者：Hiroaki Kitaoka ; MD ; FJCC ; kitaokah@kochi-u.ac.jp ; Toru Kubo ; MD ; FJCC ; Yuichi Baba ; MD ; Naohito Yamasaki ; MD ; Yoshihisa Matsumura ; MD ; FJCC ; Takashi Furuno ; MD ; Yoshinori L. Doi ; MD ; FJCC
- 关键词：Tenascin-C ; Heart failure ; Hypertrophic cardiomyopathy
- 刊名：Journal of Cardiology
- 出版年：2012
- 出版时间：March, 2012
- 年：2012
- 卷：59
- 期：2
- 页码：209-214
- 全文大小：327 K
Summary
Background and purpose
Although serum tenascin-C (TN-C) levels are related to left ventricular (LV) remodeling in patients with myocardial infarction and are useful as a prognostic biomarker of heart failure in patients with dilated cardiomyopathy, the clinical significance of TN-C levels has not yet been studied in patients with hypertrophic cardiomyopathy (HCM). Therefore, the purpose of this study is to elucidate whether serum TN-C levels are a prognostic biomarker for heart failure in patients with HCM.Methods
The relationship between serum TN-C levels and heart failure events was studied in 36 patients with HCM during follow-up.
Results
Levels of serum TN-C were 28 ¡À 13 ng/ml (range 11-80 ng/ml). Although patients with LV systolic impairment showed higher TN-C levels than those with preserved LV systolic function (33 ¡À 11 ng/ml vs. 27 ¡À 14 ng/ml; p = 0.16), TN-C levels were not related to any echocardiographic parameters. During the follow-up period of 4.8 ¡À 1.4 years, heart failure events were observed in six patients and TN-C levels in patients with events were higher than those in patients without events. Kaplan-Meier analysis showed that the prognosis was worse in patients with high TN-C levels (?9.2 ng/ml) than in those with low TN-C levels.
Conclusions
Heart failure events were more frequently observed in patients with high serum TN-C levels than in those with low TN-C levels. Serum TN-C levels may be a new prognostic biomarker for heart failure in patients with HCM.